#United States #New York #Pomerantz LLP #Aardvark Therapeutics #AARD

The Pomerantz Investigation into Aardvark Therapeutics

In an alarming turn of events, Pomerantz Law Firm has announced an investigation into claims against Aardvark Therapeutics, Inc. (NASDAQ: AARD). The firm is seeking out investors who may have suffered from potential securities fraud or other dishonest business practices perpetrated by the company and its leading officers. This investigation highlights serious concerns that have emerged following recent announcements made by Aardvark.

Background: Aardvark Therapeutics and the HERO Trial

On February 27, 2026, Aardvark released a statement indicating it was voluntarily pausing its Phase 3 trial known as the Hunger Elimination or Reduction Objective (HERO). The company cited reversible cardiac observations at elevated therapeutic doses which had been flagged during standard safety monitoring of a study involving healthy volunteers. This news had a swift and severe impact on Aardvark's stock, which plummeted by 56.2% in a matter of days, closing at $5.47 per share by March 2.

The decision to pause the study raised alarms about the company's future direction, and investors reacted negatively to the uncertainty surrounding the trial's outcomes and its implications for the drug candidate ARD-101, particularly in the context of treating hyperphagia in patients with Prader-Willi Syndrome (PWS).

As if these concerns weren't enough, on May 14, 2026, Aardvark disclosed that the U.S. Food and Drug Administration (FDA) had imposed a full clinical hold on its investigational new drug application related to ARD-101. This decision affected all ongoing clinical studies under the IND, particularly the HERO Trial. Following this announcement, Aardvark's stock suffered yet another significant loss, dropping to $4.57—a decline of 32.1% on May 15.

Investor Rights and Class Action Potential

In light of these developments, the Pomerantz law firm is reaching out to shareholders who may feel wronged by Aardvark's actions during this tumultuous period. Danielle Peyton, a representative from the firm, has emphasized that any investors affected by the stock's steep decline and the surrounding events should come forward to discuss their circumstances.

The firm's investigation is poised to establish if there were indeed breaches of fiduciary duty or securities laws that might merit a class action. Pomerantz has a storied history in advocating for investors and recovering damages from corporate misconduct, having dealt with numerous high-profile cases over its 85-year existence.

Aardvark’s Future in Question

As the investigation progresses, it raises the question of what the future holds for Aardvark Therapeutics. The ramifications of the FDA's hold and the response from investors may shape the company's strategic direction moving forward. Shareholders will be closely watching how the firm addresses these issues and whether it can restore confidence in its product pipeline.

Conclusion

With the losses mounting and investors now facing uncertainty, Pomerantz’s investigation could be a critical step towards advocating for the rights of those impacted by these financial decisions. Companies like Aardvark must navigate the fine line of innovation and safety, ensuring that investor trust is maintained while exploring groundbreaking therapies. Those involved in the case are encouraged to reach out if they believe they have suffered a loss due to Aardvark’s actions, as legal recourse may be a viable option.

For more information or to join the investigation, interested parties are advised to contact Pomerantz LLP directly. With the legal landscape in flux, it reflects a crucial period for both Aardvark and its investors.

• ---

This article is intended for general informational purposes only and should not be considered legal advice. Previous outcomes do not guarantee comparable results in future cases.